Gracilins: Spongionella-derived promising compounds for Alzheimer disease

Neuropharmacology

Volumn 93, Issue , 2015, Pages 285-293

  Leirós, Marta ^a   Alonso, Eva ^a   Rateb, Mostafa E ^b,c   Houssen, Wael E ^b,d   Ebel, Rainer ^b   Jaspars, Marcel ^b   Alfonso, Amparo ^a   Botana, Luis M ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c Beni Suef University   (Egypt)

^d UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

3xTg AD; Alzheimer disease; ERK; Gracilin; Morris water maze; Spongionella

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BETA SECRETASE 1; GLYCOGEN SYNTHASE KINASE 3BETA; GRACILIN; GRACILIN A; GRACILIN H; GRACILIN L; MITOGEN ACTIVATED PROTEIN KINASE; NEUROPROTECTIVE AGENT; TAU PROTEIN; TETRAHYDROAPLYSULPHURIN 1; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); AMYLOID PRECURSOR PROTEIN; DITERPENE; ENZYME INHIBITOR; NEUROLEPTIC AGENT; PEPTIDE FRAGMENT; PRESENILIN 1; SECRETASE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG SCREENING; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LEARNING; MOUSE; NEUROBLASTOMA CELL; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SPATIAL MEMORY; SPONGE (PORIFERA); SPONGIONELLA; ANIMAL; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; GENETICS; MAZE TEST; METABOLISM; MUTATION; NEUROBLASTOMA; PATHOLOGY; TIME; TRANSGENIC MOUSE; TUMOR CELL LINE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ANTIPSYCHOTIC AGENTS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DITERPENES; ENZYME INHIBITORS; HUMANS; MAZE LEARNING; MICE; MICE, TRANSGENIC; MUTATION; NEUROBLASTOMA; PEPTIDE FRAGMENTS; PORIFERA; PRESENILIN-1; TAU PROTEINS; TIME FACTORS;

EID: 84923927329     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2015.02.015     Document Type: Article

References (51)

1. R. Anand, K.D. Gill, and A.A. Mahdi Therapeutics of Alzheimer's disease: past, present and future Neuropharmacology 76 Pt A 2014 27 50
2. J.W. Blunt Marine natural products Nat. Prod. Rep. 20 1 2003 1 48
3. J.W. Blunt Marine natural products Nat. Prod. Rep. 21 1 2004 1 49
4. J.W. Blunt Marine natural products Nat. Prod. Rep. 22 1 2005 15 61
5. J.W. Blunt Marine natural products Nat. Prod. Rep. 23 1 2006 26 78
6. J.W. Blunt Marine natural products Nat. Prod. Rep. 24 1 2007 31 86
7. J.W. Blunt Marine natural products Nat. Prod. Rep. 25 1 2008 35 94
8. J.W. Blunt Marine natural products Nat. Prod. Rep. 26 2 2009 170 244
9. J.W. Blunt Marine natural products Nat. Prod. Rep. 27 2 2010 165 237
10. J.W. Blunt Marine natural products Nat. Prod. Rep. 28 2 2011 196 268
11. J.W. Blunt Marine natural products Nat. Prod. Rep. 29 2 2012 144 222
12. J.W. Blunt Marine natural products Nat. Prod. Rep. 30 2 2013 237 323
13. J.W. Blunt Marine natural products Nat. Prod. Rep. 31 2 2014 160 258
14. M.F. Galindo Mitochondrial biology in Alzheimer's disease pathogenesis J. Neurochem. 114 4 2010 933 945
15. M. Goedert, R.A. Crowther, and M.G. Spillantini Tau mutations cause frontotemporal dementias Neuron 21 5 1998 955 958
16. C. Grosso Bioactive marine drugs and marine biomaterials for brain diseases Mar. Drugs 12 5 2014 2539 2589
17. L.S. Honig, and R. Mayeux Natural history of Alzheimer's disease Aging (Milano) 13 3 2001 171 182
18. X. Huang Redox-active metals, oxidative stress, and Alzheimer's disease pathology Ann. N. Y. Acad. Sci. 1012 2004 153 163
19. G. Joshi, and J.A. Johnson The Nrf2-ARE pathway: a valuable therapeutic target for the treatment of neurodegenerative diseases Recent Pat. CNS Drug Discov. 7 3 2012 218 229
20. S. Lee Exonic point mutations of human tau enhance its toxicity and cause characteristic changes in neuronal morphology, tau distribution and tau phosphorylation in the lamprey cellular model of tauopathy J. Alzheimers Dis. 16 1 2009 99 111
21. M. Leiros Spongionella secondary metabolites protect mitochondrial function in cortical neurons against oxidative stress Mar. Drugs 12 2 2014 700 718
22. T. Loffler Stable mutated tau441 transfected SH-SY5Y cells as screening tool for Alzheimer's disease drug candidates J. Mol. Neurosci. 47 1 2012 192 203
23. D. Luque-Contreras Oxidative stress and metabolic syndrome: cause or consequence of Alzheimer's disease? Oxid. Med. Cell. Longev. 2014 2014 497802
24. M.P. Macias A cellular model of amyloid precursor protein processing and amyloid-beta peptide production J. Neurosci. Methods 223 2014 114 122
25. J. Madeo, and C. Elsayad The role of oxidative stress in Alzheimer 's disease J. Alzheimers Dis. Park. 3 2 2013 116
26. L. Martin Tau protein kinases: involvement in Alzheimer's disease Ageing Res. Rev. 12 1 2013 289 309
27. M.P. Mattson Pathways towards and away from Alzheimer's disease Nature 430 7000 2004 631 639
28. A.M. Mayer Marine pharmacology in 2003-4: marine compounds with anthelmintic antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiplatelet, antiprotozoal, antituberculosis, and antiviral activities; affecting the cardiovascular, immune and nervous systems, and other miscellaneous mechanisms of action Comp. Biochem. Physiol. C Toxicol. Pharmacol. 145 4 2007 553 581
29. A.M. Mayer Marine pharmacology in 2005-6: marine compounds with anthelmintic, antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiprotozoal, antituberculosis, and antiviral activities; affecting the cardiovascular, immune and nervous systems, and other miscellaneous mechanisms of action Biochim. Biophys. Acta 1790 5 2009 283 308
30. A.M. Mayer Marine pharmacology in 2007-8: marine compounds with antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiprotozoal, antituberculosis, and antiviral activities; affecting the immune and nervous system, and other miscellaneous mechanisms of action Comp. Biochem. Physiol. C Toxicol. Pharmacol. 153 2 2011 191 222
31. A.M. Mayer Marine pharmacology in 2009-2011: marine compounds with antibacterial, antidiabetic, antifungal, anti-inflammatory, antiprotozoal, antituberculosis, and antiviral activities; affecting the immune and nervous systems, and other miscellaneous mechanisms of action Mar. Drugs 11 7 2013 2510 2573
32. A.M. Mayer, and M.T. Hamann Marine pharmacology in 1999: compounds with antibacterial, anticoagulant, antifungal, anthelmintic, anti-inflammatory, antiplatelet, antiprotozoal and antiviral activities affecting the cardiovascular, endocrine, immune and nervous systems, and other miscellaneous mechanisms of action Comp. Biochem. Physiol. C Toxicol. Pharmacol. 132 3 2002 315 339
33. A.M. Mayer, and M.T. Hamann Marine pharmacology in 2000: marine compounds with antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiplatelet, antituberculosis, and antiviral activities; affecting the cardiovascular, immune, and nervous systems and other miscellaneous mechanisms of action Mar. Biotechnol. (NY) 6 1 2004 37 52
34. A.M. Mayer, and M.T. Hamann Marine pharmacology in 2001-2002: marine compounds with anthelmintic, antibacterial, anticoagulant, antidiabetic, antifungal, anti-inflammatory, antimalarial, antiplatelet, antiprotozoal, antituberculosis, and antiviral activities; affecting the cardiovascular, immune and nervous systems and other miscellaneous mechanisms of action Comp. Biochem. Physiol. C Toxicol. Pharmacol. 140 3-4 2005 265 286
35. M. Mehbub Marine sponge derived natural products between 2001 and 2010: trends and opportunities for discovery of bioactives Mar. Drugs 12 8 2014 4539 4577
36. M.A. Meraz-Rios Early onset Alzheimer's disease and oxidative stress Oxid. Med. Cell. Longev. 2014 2014 375968
37. A. Mollica Synthesis and bioactivity of secondary metabolites from marine sponges containing dibrominated indolic systems Molecules 17 5 2012 6083 6099
38. S. Mondragon-Rodriguez Phosphorylation of tau protein as the link between oxidative stress, mitochondrial dysfunction, and connectivity failure: implications for Alzheimer's disease Oxid. Med. Cell. Longev. 2013 2013 940603
39. P. Nacharaju Accelerated filament formation from tau protein with specific FTDP-17 missense mutations FEBS Lett. 447 2-3 1999 195 199
40. N. Nirmal, G.O. Praba, and D. Velmurugan Modeling studies on phospholipase A2-inhibitor complexes Indian J. Biochem. Biophys. 45 4 2008 256 262
41. S. Oddo Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular abeta and synaptic dysfunction Neuron 39 3 2003 409 421
42. D. Puzzo Behavioral assays with mouse models of Alzheimer's disease: practical considerations and guidelines Biochem. Pharmacol. 88 4 2014 450 467
43. M.E. Rateb Bioactive diterpene derivatives from the marine sponge Spongionella sp J. Nat. Prod. 72 8 2009 1471 1476
44. A. Rueda Gracilins G-I, cytotoxic bisnorditerpenes from Spongionella pulchella, and the anti-adhesive properties of gracilin B Lett. Drug Des. Discov. 3 10 2006 753 760
45. D.J. Selkoe Alzheimer's disease: genes, proteins, and therapy Physiol. Rev. 81 2 2001 741 766
46. E. Tamagno JNK and ERK1/2 pathways have a dual opposite effect on the expression of BACE1 Neurobiol. Aging 30 10 2009 1563 1573
47. V. Tell, and A. Hilgeroth Recent developments of protein kinase inhibitors as potential AD therapeutics Front. Cell. Neurosci. 7 2013 189
48. E.E. Tuppo, and L.J. Forman Free radical oxidative damage and Alzheimer's disease J. Am. Osteopath Assoc. 101 12 Suppl. Pt 1 2001 S11 S15
49. R.W. Van Soest Global diversity of sponges (Porifera) PLoS One 7 4 2012 e35105
50. X. Wang Oxidative stress and mitochondrial dysfunction in Alzheimer's disease Biochim. Biophys. Acta 1842 8 2014 1240 1247
51. Y. Zhao, and B. Zhao Oxidative stress and the pathogenesis of Alzheimer's disease Oxid. Med. Cell. Longev. 2013 2013 316523